UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 11, 2026**

bioAffinity Technologies, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-41463**	**46-5211056**
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

3300 Nacogdoches Road, Suite 216
San Antonio, Texas 78217
(Address of principal executive offices, including zip code)

(210) 698-5334
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class	Trading Symbols	Name of each exchange on which registered
Common Stock, par value $0.007 per share	BIAF	The Nasdaq Stock Market LLC (Nasdaq Capital Market)
Warrants to purchase Common Stock	BIAFW	The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On November 11, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the "Company"), issued a press release announcing that a record number of CyPath® Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company's noninvasive lung cancer test.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release issued by bioAffinity Technologies, Inc., dated November 11, 2026
104	Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 17, 2026

BIOAFFINITY TECHNOLOGIES, INC.

By: */s/ Maria Zannes*
Name: Maria Zannes
Title: President and Chief Executive Officer

Exhibit 99.1

bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test

October testing volume equals approximately 45% of all tests performed in the previous quarter

SAN ANTONIO, Texas – November 11, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease and topically delivered therapeutics for skin cancer, today announced that a record number of CyPath® Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company's noninvasive lung cancer test.

The October results demonstrate continued growth in test utilization by both established and newly ordering physicians. In October 2026, 235 CyPath Lung tests were performed, representing a 29% increase compared with October 2025. October 2026 testing volume was equivalent to approximately 45% of the total number of tests performed in Q3 2026.

"October's testing volume reflects our efforts to expand the commercial reach of CyPath Lung," said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies. "In addition to expanding physician adoption and strengthening relationships with existing customers, we are taking additional steps to expand the reach of CyPath Lung and set the stage for long-term growth. We have expanded our sales team. We are working with patient advocacy organizations to strengthen our connections within the lung cancer community, and we are seeing significant advances in our R&D to apply our proprietary technology platform to asthma and COPD."

CyPath Lung is a noninvasive test that analyzes cell populations in sputum using flow cytometry and proprietary AI to help physicians assess the likelihood of lung cancer by analyzing the lung microenvironment. The test is designed to complement existing imaging and clinical assessment and provide physicians with additional information when determining appropriate next steps for patients.

bioAffinity continues to advance its commercial strategy through direct physician engagement, distribution relationships and opportunities within government healthcare systems. The Company is focused on increasing awareness and utilization of CyPath Lung among pulmonologists and other healthcare providers while building on its growing base of ordering physicians and repeat testing activity.

About CyPath Lung

CyPath Lung by bioAffinity Technologies is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. CyPath Lung incorporates proprietary antibodies and a novel fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. In a published clinical trial of high-risk patients, CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value (NPV) in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters. The high NPV may help inform physician decision-making when evaluating whether further invasive procedures are warranted. CyPath Lung is marketed as a Laboratory Developed Test (LDT), is not intended for use as a sole diagnostic tool and should be considered alongside other clinical findings. For more information, visit www.cypathlung.com.

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA), which are administered by the Centers for Medicare & Medicaid Services. For more information, visit www.bioaffinitytech.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent may identify forward-looking statements, although not all forward-looking statements contain these words. These forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially, including the Company's ability to sustain physician demand and convert commercial efforts into reimbursable testing and revenue; variability in monthly testing volume; reimbursement coverage, payment rates, denials and collection delays; the ability to establish and maintain distribution relationships and obtain government healthcare business; and the possibility that research will not establish the clinical performance or utility needed for new applications or lead to commercially viable products. Historical testing volume does not establish future growth, revenue or profitability. Additional risks and uncertainties are described in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Readers are cautioned not to place undue reliance on forward-looking statements. These statements speak only as of the date of this release, and the Company undertakes no obligation to update them, except as required by applicable law.

Contact

bioAffinity Technologies
Julie Anne Overton
Director of Communications
investors@bioaffinitytech.com